PRRT2 and cancer: Whereas PKCs have generally been considered pro-oncogenic kinases, different isoenzymes are inactivated by loss-of-function mutations in a variety of cancers, thus supporting a potential tumor-suppressive rather than tumor-promoting role for distinctive PKC isoenzymes [334].